MedPath
Found 25 clinical trials|View Analysis
Sort by:

A Study of HS-20124 in Patients with Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Solid Cancer
Interventions
Drug: HS-20124 (Phase Ia:Dose escalation )
First Posted Date
2025-01-08
Last Posted Date
2025-01-08
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
450
Registration Number
NCT06763159
Locations
🇨🇳

Affiliated Cancer Hospital of Fudan University, Shanghai, Shanghai, China

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

Phase 1
Not yet recruiting
Conditions
Osteosarcoma
Soft Tissue Sarcoma (STS)
Interventions
First Posted Date
2024-11-21
Last Posted Date
2024-11-21
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
448
Registration Number
NCT06699576

A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Phase 3
Not yet recruiting
Conditions
Psoriasis
Interventions
Drug: HS-10374 6mg tablets
Drug: HS-10374-matched placebo tablets
First Posted Date
2024-11-04
Last Posted Date
2024-11-04
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
375
Registration Number
NCT06672393
Locations
🇨🇳

Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China

A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy

Phase 2
Not yet recruiting
Conditions
Immunoglobulin a Nephropathy
Interventions
Drug: HS-10390
Drug: Irbesartan
First Posted Date
2024-10-10
Last Posted Date
2024-10-10
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
90
Registration Number
NCT06635772

Phase Ib Trial of HS-20117 in Combination with Other Drugs in Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Solid Tumors
Non-Small Cell Lung Cancer
Colorectal Cancer
Interventions
Drug: HS-20117 combined Platinum-containing chemotherapy
Drug: HS-20117 combined HS-20093
Drug: HS-20117 combined HS-20093 and 5-FU
First Posted Date
2024-10-01
Last Posted Date
2024-10-01
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
780
Registration Number
NCT06621563

A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Phase 2
Not yet recruiting
Conditions
Myelodysplastic Syndromes
Anemia
MDS
Bone Marrow Disease
Interventions
Drug: HS-20106
First Posted Date
2024-09-13
Last Posted Date
2024-09-19
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
176
Registration Number
NCT06594965
Locations
🇨🇳

Institute of Hematology and Blood Diseases Hospital, Tianjin, Tianjin, China

A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer

Phase 3
Not yet recruiting
Conditions
Limited-stage Small-cell Lung Cancer
Interventions
Drug: HS-20093
First Posted Date
2024-07-30
Last Posted Date
2024-07-30
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
406
Registration Number
NCT06526624

ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

Phase 3
Recruiting
Conditions
Small Cell Lung Cancer
Interventions
Drug: HS-20093
Drug: Topotecan
First Posted Date
2024-07-12
Last Posted Date
2024-10-16
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
460
Registration Number
NCT06498479
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

and more 6 locations

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 2
Not yet recruiting
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Drug: HS-20117
Drug: Aumolertinib
First Posted Date
2024-05-16
Last Posted Date
2024-05-20
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
1080
Registration Number
NCT06417008

A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

Phase 2
Not yet recruiting
Conditions
Vasomotor Symptoms
Interventions
Drug: HS-10384 tablet Dose 1
Drug: HS-10384 tablet Dose 2
Drug: HS-10384-matched placebo tablets
First Posted Date
2024-05-01
Last Posted Date
2024-05-01
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
195
Registration Number
NCT06393673
Locations
🇨🇳

Chinese Academy of Medical Sciences (CAMS)Peking Union Medical College (PUMC), Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath